摘要
To the Editor: We read with great interest the article by Dr. Vitale et al.[1], which developed an ITA.LI.CA scoring system to improve the prognostic utility for patients with re-staging hepatocellular carcinoma (HCC) before additional therapies. We appreciate the authors’ work and believe that the study has important value in guiding reasonable treatments for HCC. Herein, we would like to raise the following comments.
